Alicia Morgans, MD, MPH, discusses a potentially practice-changing abstract from the 2025 American Society of Clinical ...

FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies.

Recent advances in RAS-targeted therapies revolutionize treatment for gastrointestinal cancers, promising improved outcomes and new clinical strategies for oncologists.

Pembrolizumab combined with chemoradiation shows promising long-term efficacy and safety in treating advanced non-small cell ...

Shahzad Raza, MD, discusses new data from the phase 2 RedirecTT-1 study of talquetamab with teclistamab for the treatment of patients with relapsed/refractory multiple myeloma and extramedullary ...

During a live event, Taewoong Choi, MD, discussed the potential use of quadruplet in transplant-ineligible multiple myeloma ...

A study reveals significant genomic differences in metastatic prostate cancer among veterans, highlighting the need for ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard ...

Daratumumab effectively delays multiple myeloma relapse by monitoring minimal residual disease, offering hope for improved ...

Asciminib shows superior tolerability over nilotinib in newly diagnosed CML-CP patients, reducing treatment discontinuation ...